On July 21, ArchiMed announced that it purchased ZimVie for $730 million. ZimVie stockholders will receive $19 in cash for each share of ZimVie common stock outstanding at the closing of the transaction.
ZimVie is a global life sciences leader in the dental market that develops, manufactures and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. Zimvie spun out of Zimmer Biomet in 2022 and has since broken off into smaller pieces.
ArchiMed is an independent private equity investment firm focused exclusively on the healthcare industry. It has directly managed and invested in more than 80 companies with a combined value of $50 billion. Its mix of operational, medical, scientific and financial expertise allows the ArchiMed team to serve as a strategic and financial partner to European and North American small and middle-market businesses.
Centerview Partners is serving as exclusive financial advisor to ZimVie, and Cravath, Swaine & Moore LLP is serving as legal advisor. UBS Investment Bank is serving as exclusive financial advisor to ArchiMed, and Latham & Watkins LLP is serving as legal advisor.
Upon completion of the transaction, ZimVie will become a privately held company and ZimVie’s shares will no longer be listed on the Nasdaq. The per share price represents a premium of 99% to the ZimVie 90-day volume-weighted average price of $9.57 per share.
According to data captured in the LevinPro HC database, this transaction marks the 51st Medical Devices transaction of the year. Throughout all of 2024, there were 87 Medical Devices deals reported. This also represents ArchiMed’s first acquisition of 2025; in 2024, the company completed three transactions.
